Research on the multi-dimensional value assessment framework for new antidiabetic drugs to support evidence-informed medical insurance decision-making
- VernacularTitle:支持医保知证决策的降糖新药多维价值评估框架研究
- Author:
Feifei YAN
1
;
Jingyu CHEN
1
;
Jiaran CHEN
1
;
Chen PAN
1
;
Guohua WANG
2
;
Jinsong GENG
1
Author Information
1. Dept. of Medical Informatics，Medical School of Nantong University，Jiangsu Nantong 226001，China
2. National Clinical Research Center for Geriatric Diseases，Xuanwu Hospital，Capital Medical University，Beijing 100053，China
- Publication Type:Journal Article
- Keywords:
new antidiabetic drugs;
evidence-informed decision-making;
medical insurance;
value assessment framework
- From:
China Pharmacy
2025;36(13):1563-1567
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish a multi-dimensional value assessment framework for new antidiabetic drugs based on multi-criteria decision analysis theory， thus providing a theoretical framework and methodology for evidence-informed medical insurance decision-making. METHODS Firstly， multi-dimensional evidence was searched and obtained to provide reliable data for the establishment of the framework. Secondly， in terms of the obtained evidence， the value assessment framework was preliminarily constructed. Its structure， main core criteria， and contextual criteria were determined through focus group discussion. Finally， the criteria and sub-criteria of the framework and their weights were further determined， reasons for inclusion of sub-criteria and the reasonableness of rating scores were evaluated， and methods of assessment were optimized through expert consultation. RESULTS The multi-dimensional value assessment framework for new antidiabetic drugs was composed of core criteria and contextualized criteria， which could be used for quantitative and qualitative value assessment of new drugs， respectively. The core criteria consisted of five dimensions， with affordability （6.31） having the highest weighting score， followed by comparative effectiveness （6.20）， comparative safety （6.01）， cost-effectiveness （5.89）， and quality of evidence （5.46）. After the normalization of weight within sub-criteria， the budget impact on medical insurance had the highest standardized weight， followed by the control of glycated hemoglobin and patient affordability. The contextual criteria included two dimensions， i. e.， innovation and equity. CONCLUSIONS The assessment framework integrates evidence， stakeholders’ values， and decision contexts to enable a multi- dimensional and evidence-based assessment of the value of new antidiabetic drugs.
